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DISPOSABLE LIVES:
COVID-19, VACCINES, AND THE UPRISING
Matiangai Sirleaf*
“If I can be provocative, shouldn’t this study be done in Africa, where there
are no masks, no treatment, no intensive care, a bit like some studies on AIDS or
among prostitutes. We try things, because we know they . . . are highly exposed and
they don’t protect themselves. What do you think about that?”
— Jean-Paul Mira, Head of the Intensive Care Unit at the Cochin
Hospital in Paris, April 1, 20201
“You’re right . . . . We’re currently thinking in parallel about a study in
Africa with the same type of approach . . . . I think a call has been issued or will be
issued and I think we are going to consider it.”
— Camille Locht, Research Director at the French Institute of Health
and Medical Research, Inserm, April 1, 20202
INTRODUCTION
Two French doctors appeared on television and publicly discussed potentially utilizing African subjects in experimental trials for a tuberculosis
vaccine as an antidote to the novel coronavirus (COVID-19).3 Tedros
Adhanom Ghebreyesus, the Director-General of the World Health Organization (WHO), denounced these kinds of racist remarks as a “hangover
from ‘colonial mentality’”4 and maintained that “Africa can’t and won’t be

* Nathan Patz Professor of Law, University of Maryland Francis King Carey School of
Law. Much gratitude to Aziza Ahmed and Timothy Lovelace for their helpful comments on
an earlier draft.
1. What French Doctors and the WHO Really Said About Africa and Vaccine Testing,
Euronews, https://www.euronews.com/2020/04/07/what-french-doctors-and-the-who-reallysaid-about-africa-and-vaccine-testing [https://perma.cc/ZFQ3-6H89] (last updated Aug. 4,
2020).
2. Id.
3. James Ojo, Watch: Outrage as French Doctors Discuss Testing COVID-19 Vaccine
in Africa, Cable Lifestyle (Apr. 2, 2020), https://lifestyle.thecable.ng/watch-outrage-asfrench-doctors-discuss-testing-covid-19-vaccine-in-africa [https://perma.cc/2J3K-5MSE].
4. Coronavirus: Africa Will Not Be Testing Ground for Vaccine, Says WHO, BBC News
(Apr. 6, 2020), https://www.bbc.com/news/world-africa-52192184 [https://perma.cc/
EYN8-UZEG].
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a testing ground for any vaccine.”5 The fallout on social media was similarly swift, with Samuel Eto’o, a Cameroonian football legend, referring to
the doctors as “[d]es assasins”6 and several others questioning the motives
behind testing a vaccine on the African continent.7 The dialogue between
the doctors and the strong reactions to their statements reopen the
wounds of Black, Indigenous, and other people of color’s lives being
treated as disposable.
This Piece connects how racialized notions regarding which lives are
disposable are reﬂected widely in the areas of health and human rights.
The presumed expendability of Black lives is made manifest from systemic
police violence, to the devastating racially disproportionate impact of
COVID-19,8 to historic and ongoing medical experimentation, and to
inequitable vaccine access.9 The twin pandemics of systemic racism and
COVID-19 have heightened the visibility of the disposability with which
society views the lives of people of color. The cumulative effect of this
disposability furthers the devaluation of subordinated groups. Through
exploring the theme of disposability, this Piece clariﬁes the roles of
international human rights law, global public health, and international
intellectual property law in either advancing racial justice efforts or
contributing toward racial subordination. This period of racial reckoning
and reform creates an opening to challenge the racial status quo in these
areas and beyond.
I. DISPOSABLE LIVES AND THE UPRISING
The ongoing uprising challenges the assumption of disposability of
Black lives in the United States and elsewhere. The seemingly unrelenting
5. Id.
6. Samuel Eto’o (@SamuelEtoo), Twitter (Apr. 2, 2020), https://twitter.com/
SamuelEtoo/status/1245655021162659841?lang=en (on ﬁle with the Columbia Law Review).
7. See, e.g., Musa Okwonga, The French Doctors Who Wanted to Test Vaccines on
Africans and Western Medicine’s Dark History, Quartz Afr. (Apr. 10, 2020),
https://qz.com/africa/1836272/french-doctors-say-test-covid-19-vaccine-on-africans-sparkfury (on ﬁle with the Columbia Law Review); Rim-Sarah Alouane (@RimSarah), Twitter (Apr.
2, 2020), https://twitter.com/RimSarah/status/1245680422614446081 (on ﬁle with the
Columbia Law Review).
8. Jazmyn T. Moore, Jessica N. Ricaldi, Charles E. Rose, Jennifer Fuld, Monica Parise,
Gloria J. Kang, Anne K. Driscoll, Tina Norris, Nana Wilson, Gabriel Rainisch, Eduardo
Valverde, Vladislav Beresovsky, Christine Agnew Brune, Nadia L. Oussayef, Dale A. Rose,
Laura E. Adams, Sindoos Awel, Julie Villanueva, Dana Meaney-Delman & Margaret A.
Honein, Disparities in Incidence of COVID-19 Among Underrepresented Racial/Ethnic
Groups in Counties Identiﬁed as Hotspots During June 5–18, 2020—22 States, February–
June 2020, 69 Morbidity & Mortality Wkly. Rep. 1122, 1123 (2020) (“A high percentage of
cases in hotspot counties are among persons of color.”).
9. Uché Blackstock & Oni Blackstock, Opinion, White Americans Are Being
Vaccinated at Higher Rates than Black Americans. Such Inequity Cannot Stand., Wash. Post
(Feb. 1, 2021), https://www.washingtonpost.com/opinions/2021/02/01/racial-inequalitycovid-vaccine (on ﬁle with the Columbia Law Review).
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onslaught of police violence against Black people in the United States has
resulted in many lives lost, both seen and unseen. Notoriously, Derek
Chauvin, a Minneapolis police officer, kneed George Floyd to death for
over nine minutes.10 During this time, George Floyd told officers, “I can’t
breathe” more than twenty times while the officer’s knee remained on his
neck.11 The officers treated him as disposable. In Louisville, several police
officers shot and killed Breonna Taylor, an EMT worker who was sleeping
when the police forcibly entered her home attempting to enforce a noknock warrant.12 Additionally, a former police officer killed Ahmaud
Arbery for “jogging while Black” in Brunswick, Georgia.13 The banal
circumstances surrounding their deaths indicate the precariousness of
Black lives and the ease with which our lives can be disposed. The public
health community has belatedly recognized that addressing police
violence is a public health issue.14
Mr. Floyd’s death vividly illustrates the relationship between police
brutality, systemic racism, and health equity. The Hennepin County
Medical Examiner’s autopsy report indicates that he was positive for
COVID-19 at the time of his death.15 It also observes that he was likely
asymptomatic with persistent positivity from a previous infection.16 Mr.
Floyd’s positive test for COVID-19 on April 3, 2020 occurred nearly eight

10. Nicholas Bogel-Burroughs, Prosecutors Say Derek Chauvin Knelt on George Floyd
for 9 Minutes 29 Seconds, Longer than Initially Reported., N.Y. Times (Mar. 30, 2021),
https://www.nytimes.com/2021/03/30/us/derek-chauvin-george-ﬂoyd-kneel-9-minutes29-seconds.html (on ﬁle with the Columbia Law Review).
11. Maanvi Singh, George Floyd Told Officers ‘I Can’t Breathe’ More than 20 Times,
Transcripts Show, Guardian (July 9, 2020), https://www.theguardian.com/us-news/2020/
jul/08/george-ﬂoyd-police-killing-transcript-i-cant-breathe
[https://perma.cc/HX4NUNZJ].
12. Amina Elahi, ‘Sleeping While Black’: Louisville Police Kill Unarmed Black Woman,
NPR (May 13, 2020), https://www.npr.org/2020/05/13/855705278/sleeping-while-blacklouisville-police-kill-unarmed-black-woman [https://perma.cc/35EE-GNLC].
13. Zack Beauchamp, Ahmaud Arbery and the Dangers of Running While Black, Vox
(May 8, 2020), https://www.vox.com/policy-and-politics/2020/5/8/21250914/ahmaudarbery-mcmichael-arrest-black-men-exercise (on ﬁle with the Columbia Law Review); see also
Marie Andrusewicz, Georgia Attorney General Asks for DOJ Probe into Handling of
Ahmaud Arbery Case, NPR (May 10, 2020), https://www.npr.org/2020/05/10/
853581211/georgia-attorney-general-asks-for-doj-probe-into-handling-of-ahmaud-arberycase [https://perma.cc/Q7A6-JYMW].
14. See, e.g., Addressing Law Enforcement Violence as a Public Health Issue, Am. Pub.
Health Ass’n (Nov. 13, 2018), https://www.apha.org/policies-and-advocacy/public-healthpolicy-statements/policy-database/2019/01/29/law-enforcement-violence
[https://perma.cc/LQ52-FWKM]; see also Sirry Alang, Donna McAlpine, Ellen McCreedy
& Rachel Hardeman, Police Brutality and Black Health: Setting the Agenda for Public
Health Scholars, 107 Am. J. Pub. Health 662, 662 (2017).
15. Andrew M. Baker, Hennepin County Medical Examiner’s Office Autopsy Report 3
(June 1, 2020), https://www.hennepin.us/-/media/hennepinus/residents/public-safety/
documents/ﬂoyd-autopsy-6-3-20.pdf [https://perma.cc/Z6RG-Z3J7].
16. Id.
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weeks prior to when police murdered him.17 The Hennepin County
autopsy report found that Mr. Floyd went into cardiopulmonary arrest
while the police restrained him and that the police compressed his neck.18
An independent autopsy report commissioned by the Floyd family found
that his death was due to “asphyxiation from sustained pressure” when
Minneapolis police officers compressed his neck and his back.19 It is telling
that structural racism manifested in such a way that over Mr. Floyd’s brief
life, he was more likely to encounter things that we know jeopardize life
and limb—like systemic police violence and the racialized health inequities witnessed with COVID-19.20
The ongoing racial reckoning inspired in part by Mr. Floyd’s death
challenges the disposable nature with which his life and those of countless
others are regarded. During the uprising, people across the globe joined
together demanding full equality, accountability, and an end to police brutality and systemic racial injustice.21 In the United States, the response to
the Black Lives Matter uprising and allies protesting racial subordination
included substantial militarization with armored vehicles, curfews, tear
gas, pepper spray, and rubber and wooden bullets.22 The ongoing racial
reckoning has illuminated how quickly and swiftly some states are willing
to deploy the military and the police to quell those agitating for racial
justice. This must be read against the drastically different state responses
to the anti-lockdown protests occurring across the United States during
the COVID-19 pandemic, which are characterized by the police showing

17. Id.
18. Id. at 1.
19. Scott Neuman, Medical Examiner’s Autopsy Reveals George Floyd Had Positive
Test for Coronavirus, NPR (June 4, 2020), https://www.npr.org/sections/live-updatesprotests-for-racial-justice/2020/06/04/869278494/medical-examiners-autopsy-revealsgeorge-ﬂoyd-had-positive-test-for-coronavirus [https://perma.cc/6CGE-7STC].
20. Ruqaiijah Yearby, Structural Racism: The Root Cause of the Social Determinants
of Health, Petrie Flom Ctr.: Bill of Health (Sept. 22, 2020), https://blog.petrieflom.law.
harvard.edu/2020/09/22/structural-racism-social-determinant-of-health [https://perma.cc/
EGD2-LGW7].
21. Damien Cave, Livia Albeck-Ripka & Iliana Magra, Huge Crowds Around the Globe
March in Solidarity Against Policy Brutality, N.Y. Times (June 6, 2020),
https://www.nytimes.com/2020/06/06/world/george-ﬂoyd-global-protests.html (on ﬁle
with the Columbia Law Review) (last updated June 9, 2020).
22. Tom Nolan, Militarization Has Fostered a Policing Culture that Sets Up Protesters
as ‘The Enemy’, Rice: Kinder Inst. for Urb. Rsch. (June 10, 2020), https://kinder.rice.edu/
urbanedge/2020/06/10/police-brutality-militarization-racism-protests
[https://perma.cc/94RC-SF52]; Liz Szabo, Jay Hancock, Kevin McCoy, Donovan Slack &
Dennis Wagner, Fractured Skulls, Lost Eyes: Police Break Their Own Rules when Shooting
Protesters with ‘Rubber Bullets’, USA Today (June 19, 2020), https://www.usatoday.com/
in-depth/news/nation/2020/06/19/police-break-rules-shooting-protesters-rubber-bulletsless-lethal-projectiles/3211421001 [https://perma.cc/5WJC-GAFE] (last updated Sept. 11,
2020).
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phenomenal restraint.23 Juxtaposing the two shows starkly how efforts to
enforce the racial status quo and those that challenge racial hierarchy are
regarded. The knowledge that those most detrimentally impacted by
COVID-19 belong to different racial groups than the majority White24 antilockdown protestors informed the grievance and entitlement of those
seeking the premature lifting of COVID-19 restrictions. The implicit
question was: Since the suffering and disposability associated with racial
health inequities has historically been normalized, why should COVID-19
be treated any differently and require more mutual regard and concern
for subordinated groups?
II. DISPOSABLE LIVES AND RACIAL HEALTH DISPARITIES
The failure to protect historically subordinated groups has meant that
Black people in the United States are dying at approximately 1.5 times the
rate of White people from COVID-19.25 Additionally, Black lives lost
account for nearly 20% of the deaths across the United States where race
is known.26 Signiﬁcantly, the glaring racial health disparities observed with
23. Aymann Ismail, The Anti-Lockdown Protests Prove Police Know How to Treat
Protesters Fairly, Slate (May 28, 2020), https://slate.com/news-and-politics/2020/05/policeresponse-george-floyd-minneapolis-shutdowns.html [https://perma.cc/DL3C-NG6A].
24. The author capitalizes the “W” in White in this Piece, contrary to the typical
practice of the Columbia Law Review, to render Whiteness visible and avoid unparallel terms.
The capitalization of White does not imply the existence of a single ethnic group. See Ann
Thúy Nguyễn & Maya Pendleton, Recognizing Race in Language: Why We Capitalize
“Black” and “White”, Ctr. for the Study of Soc. Pol’y (Mar. 23, 2020), https://cssp.org/
2020/03/recognizing-race-in-language-why-we-capitalize-black-and-white [https://perma.cc/
AP5K-PDAR] (“To not name ‘White’ as a race is, in fact, an anti-Black act which frames
Whiteness as both neutral and the standard.”); see also Kwame Anthony Appiah, The Case
for Capitalizing the B in Black, Atlantic (June 18, 2020), https://www.theatlantic.com/
ideas/archive/2020/06/time-to-capitalize-blackand-white/613159 (on ﬁle with the
Columbia Law Review) (“Racial identities were not discovered but created . . . and we must
all take responsibility for them. Don’t let them disguise themselves as common nouns and
adjectives. Call them out by their names.”); Nell Irvin Painter, Opinion, Why ‘White’ Should
Be Capitalized, Too, Wash. Post (July 22, 2020), https://www.washingtonpost.com/
opinions/2020/07/22/why-white-should-be-capitalized (on ﬁle with the Columbia Law
Review) (“[W]hite Americans have had the choice of being something vague, something
unraced and separate from race. A capitalized ‘White’ challenges that freedom, by
unmasking ‘Whiteness’ as an American racial identity as historically important as
“Blackness”—which it certainly is.”); Eve L. Ewing, I’m a Black Scholar Who Studies Race.
Here’s Why I Capitalize ‘White.’, Medium (July 2, 2020), https://zora.medium.com/im-ablack-scholar-who-studies-race-here-s-why-i-capitalize-white-f94883aa2dd3 [https://perma.cc/
89EP-39J2] (“Whiteness is . . . a speciﬁc social category that confers identiﬁable and
measurable social beneﬁts.”); Kanya Stewart, NABJ Statement on Capitalizing Black and
Other Racial Identiﬁers, Nat’l Ass’n of Black Journalists (June 11, 2020),
https://www.nabj.org/news/news.asp?id=512370 (on ﬁle with the Columbia Law Review).
25. The COVID Racial Data Tracker, COVID Tracking Project at The Atlantic,
https://covidtracking.com/race [https://perma.cc/J43D-D4E9] (last visited Feb. 16,
2021).
26. Jeremy A.W. Gold, Lauren M. Rossen, Farida B. Ahmad, Paul Sutton, Zeyu Li,
Phillip P. Salvatore, Jayme P. Coyle, Jennifer DeCuir, Brittney N. Baack, Tonji M. Durant,
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COVID-19 are not the result of innate susceptibility in historically
subordinated groups.27 Accordingly, focusing on preexisting health
conditions like hypertension, diabetes, obesity, and the higher prevalence
of cardiovascular disease among Black people—which can make for
greater and more severe and deadly complications with COVID-1928—
provides an incomplete picture. Instead, structural factors that ensure that
Black people are “more likely to encounter those things that we know
compromise health—like inaccessible or biased health care providers,
inadequate schools and education systems, unemployment, hazardous
jobs, unsafe housing, and violent, polluted communities”29—provide a
more robust explanation for the racial disparities witnessed with COVID19. For instance, those with higher incomes are better able to follow social
distancing guidelines, while lower-income individuals are not,30 and
people of color are overrepresented among “essential workers.”31 For
example, Black workers are about one in nine workers overall in the
United States, yet they make up about one in six of all front-line-industry
workers.32 Essential personnel employed in transportation, sanitation,
retail, and other public-facing sectors tend to face greater risks from
COVID-19 because such jobs require greater contact with the public and
have minimal structural protections like paid sick days and adequate

Kenneth L. Dominguez, S. Jane Henley, Francis B. Annor, Jennifer Fuld, Deborah L. Dee,
Achuyt Bhattarai & Brendan R. Jackson, Race, Ethnicity, and Age Trends in Persons Who
Died from COVID-19—United States, May–August 2020, 69 Morbidity & Mortality Wkly
Rep. 1517, 1518 (2020).
27. Khiara M. Bridges, The Many Ways Institutional Racism Kills Black People, Time
(June 11, 2020), https://time.com/5851864/institutional-racism-america [https://perma.cc/
2UF5-BDSN]; see also Ladan Golestaneh, Joel Neugarten, Molly Fisher, Henny H. Billett,
Morayma Reyes Gil, Tanya Johns, Milagros Yunes, Michele H. Mokrzycki, Maria Coco, Keith
C. Norris, Hector R. Perez, Shani Scott, Ryung S. Kim & Eran Bellin, The Association of
Race and COVID-19 Mortality, 25 EClinicalMedicine 1, 6 (2020) (“Black patients engaged
in care did suffer disproportionate higher mortality in the COVID period . . . .”).
28. See, e.g., Kristen M.J. Azar, Zijun Shen, Robert J. Romanelli, Stephen H. Lockhart,
Kelly Smits, Sarah Robinson, Stephanie Brown & Alice R. Pressman, Disparities in Outcomes
Among COVID-19 Patients in a Large Health Care System in California, 39 Health Affs.
1253, 1260–61 (2020); Manish Pareek, Mansoor N. Bangash, Nilesh Pareek, Daniel Pan,
Shirley Sze, Jatinder S. Minhas, Wasim Hanif & Kamlesh Khunti, Ethnicity and COVID-19:
An Urgent Public Health Research Priority, 395 Lancet 1421, 1421–22 (2020).
29. Bridges, supra note 27.
30. Nicholas W. Papageorge, Matthew V. Zahn, Michèle Belot, Eline van den BroekAltenburg, Syngjoo Choi, Julian C. Jamison & Egon Tripodi, Socio-Demographic Factors
Associated with Self-Protecting Behavior During the COVID-19 Pandemic, 34 J. Population
Econ. 691, 693–94 (2021).
31. Dion Rabouin, Black Workers Overrepresented in Essential Work During
Coronavirus Pandemic, Axios (June 3, 2020), https://www.axios.com/black-workersessential-coronavirus-c502fc2e-a4fc-4c4f-ae0c-722a50d74ecd.html [https://perma.cc/7BKAZPQU].
32. Elise Gould & Valerie Wilson, Econ. Pol’y Inst., Black Workers Face Two of the
Most Lethal Preexisting Conditions for Coronavirus—Racism and Economic Inequality 4
(2020), https://ﬁles.epi.org/pdf/193246.pdf [https://perma.cc/LTZ2-H2N2].
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health insurance.33 The racialized health disparities of the COVID-19
pandemic have vividly exposed systemic racism and clariﬁed which
communities are deemed disposable.
The COVID-19 pandemic implicates several fundamental human
rights, including protections against the arbitrary deprivation of life and
the “right of everyone to the enjoyment of the highest attainable standard
of physical and mental health.”34 Under the International Covenant on
Economic, Social and Cultural Rights (ICESCR), affected states are to take
primary responsibility to prevent, treat, and control diseases.35 Additionally, a fundamental principle of economic, social, and cultural rights is that
a state should “take steps . . . to the maximum of its available resources,
with a view to achieving progressively” the right to health as well as other
economic, social, and cultural rights.36 Notably, only state parties to the
Covenant on Economic, Social and Cultural Rights are accountable for
compliance with it.37 Moreover, under the ICESCR, state parties
“undertake to prohibit and to eliminate racial discrimination in all its
forms and to guarantee the right of everyone, without distinction as to
race, color, or national or ethnic origin, to equality before the law” in the
right to public health, amongst others.38
Further, the International Covenant on the Elimination of All Forms
of Racial Discrimination (CERD) regime broadly deﬁnes racial discrimination to encompass any “distinction, exclusion, restriction or preference
based on race, color, descent, or national or ethnic origin which has the
purpose or effect of nullifying or impairing the recognition, enjoyment or
33. Celine McNicholas & Margaret Poydock, Who Are Essential Workers? A
Comprehensive Look at Their Wages, Demographics, and Unionization Rates, Econ. Pol’y
Inst.: Working Econ. Blog. (May 19, 2020), https://www.epi.org/blog/who-are-essentialworkers-a-comprehensive-look-at-their-wages-demographics-and-unionization-rates
[https://perma.cc/3MSW-4A3G].
34. See International Covenant on Civil and Political Rights art. 6(1), Dec. 16, 1996,
999 U.N.T.S. 171 (“Every human being has the inherent right to life.”); International
Covenant on Economic, Social and Cultural Rights art. 12(1), Dec. 16, 1966, 993 U.N.T.S.
3 [hereinafter ICESCR].
35. ICESCR, supra note 34, art. 12(2)(c).
36. Id. art. 2.
37. See, e.g., id. (requiring state parties to take steps to realize the rights recognized in
the Covenant). Some countries have not recognized socioeconomic rights as legally binding
primary obligations. See International Covenant on Economic, Social and Cultural Rights,
UN Treaty Collection, https://treaties.un.org/doc/Publication/MTDSG/Volume%20I/
Chapter%20IV/IV-3.en.pdf (on ﬁle with the Columbia Law Review) (last visited Sept. 28,
2019) (noting that the Covenant has 171 state parties). Notably, the United States, Palau,
the Comoros, and Cuba have not ratiﬁed the treaty. Id.
38. International Convention on the Elimination of All Forms of Racial Discrimination
art. 5, Dec. 21, 1965, 660 U.N.T.S. 195 [hereinafter CERD]; see also ICESCR, supra note 34,
art. 2(2) (“States Parties to the present Covenant undertake to guarantee that the rights
enunciated in the present Covenant will be exercised without discrimination of any kind as
to race, colour, sex, language, religion, political or other opinion, national or social origin,
property, birth or other status.”).
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exercise . . . of human rights and fundamental freedoms in the political,
economic, social, cultural or any other ﬁeld of public life.”39 International
human rights law explicitly allows claims based on disparate impact by
allowing discrimination claims based on effect.40 Signiﬁcantly, the CERD
framework for combatting discrimination is more expansive than the
United States’ equal protection jurisprudence, which primarily focuses on
purposive discrimination. Moreover, the availability of disparate impact
claims in the United States has been severely hampered due to requirements that claims reach a certain threshold level of signiﬁcance and
demonstrate a causal relationship, and by the business necessity defense.41
Internationally, disparate impact claims have not been hollowed out to the
same extent, which is welcome news for those hoping to challenge racialized global health inequities seen with COVID-19.
CERD potentially creates an avenue for destabilizing racialized health
inequities, because under the Convention, state parties are supposed to
“take effective measures to review governmental, national and local policies, and to amend, rescind or nullify any laws and regulations which have
the effect of creating or perpetuating racial discrimination wherever it
exists.”42 The CERD regime is potentially very useful for addressing
racialized health inequities because its applicability goes beyond laws and
policies that are invidious by design. By focusing on the impact and effects
of laws, policies, and actions, the CERD regime supplies fertile ground for
generating creative challenges to racialized health inequities observed
with COVID-19.
While the CERD framework is laudable in signiﬁcant ways, it faces
several obstacles in effectively combatting racialized health inequities. For
example, Article 2 of the Convention provides:
State Parties shall, when the circumstances so warrant, [to
account for] the social, economic, cultural and other ﬁelds,
special and concrete measures to ensure the adequate
development and protection of certain racial groups or
individuals belonging to them, for the purpose of guaranteeing
them the full and equal enjoyment of human rights and
fundamental freedoms.43
CERD’s state-centric framework prioritizes “groups or individuals
belonging” to states and may fundamentally curtail the ability to raise
transnational or global racial justice claims.44 Further, the Convention envisions the creation of limited state-based programs when both global and
39. CERD, supra note 38, art. 1 (emphasis added).
40. Comm. on the Elimination of Racial Discrimination, Rep. of the Comm. on the
Elimination of Racial Discrimination, U.N. Doc. A/48/18, at 115 (Sept. 15, 1993).
41. Mary Crossley, Disparate Impact in Law and Bioethics 9 (Sept. 27, 2019) (on ﬁle
with the Columbia Law Review).
42. CERD, supra note 39, art. 2(1)(c).
43. Id. art. 2.
44. Id. art. 1(4).
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state interventions are necessary to remedy global health inequities witnessed with COVID-19. Additionally, the Convention cautions that any
affirmative action measures “shall in no case entail as a consequence the
maintenance of unequal or separate rights for different racial groups after
the objectives for which they were taken have been achieved.”45 This
temporal limitation could be read narrowly in ways that inhibit the ability
to address the continued effects of racial subordination in health that
inform the trajectory of the COVID-19 pandemic. Alternatively, this
provision could theoretically apply until state actors achieve substantive
equality in health.
Overall, the CERD regime potentially creates a useful platform for
legal and institutional reform. Ultimately, addressing the impact of racial
inequities in global health exhibited during the COVID-19 pandemic
requires signiﬁcant legal and institutional restructuring to shift how
people, society, and laws respond to diseases depending on which racial
populations are deemed disposable.46
III. DISPOSABLE LIVES AND EXPERIMENTAL TRIALS
The discussion between the doctors in the Introduction reveals the
way that disposability and medical neocolonialism are intertwined and
reﬂexively invoked.47 The concept of medical neocolonialism aptly
characterizes the pattern of extraction of resources from Black and other
people of color for experimental clinical trials.48 The knowledge generated from this research is subsequently utilized for the development of new
treatments and drugs. However, the subjects of the research and their
communities generally do not share equitably in the beneﬁts of these
innovations.49 Medical neocolonialism draws on many of the characteristics of historical colonialism in that it is similarly driven by economic
dependence, exploitation, inequality, and the treatment of communities
of color as disposable.
Given the stark racial disparities witnessed with COVID-19, there is
understandable skepticism that COVID-19 vaccines will be used to help
subordinated groups, since we have generally not been protected in the
ﬁrst place. An Associated Press nationwide poll conducted between May
14–18, 2020 (approximately a week before the police killed Mr. Floyd),
revealed that, while 56% of White people were willing to take a potential
COVID-19 vaccine, only 37% of Latinx and 25% of Black people would do
45. Id.
46. For further discussion, see generally Matiangai Sirleaf, Racial Valuation of Diseases,
67 UCLA L. Rev. 1820 (2021).
47. See Jin Un Kim, Obinna Oleribe, Ramou Njie & Simon D. Taylor-Robinson, A
Time for New North-South Relationships in Global Health, 10 Int’l J. Gen. Med. 401, 407
(2017).
48. See id. at 401–03.
49. Id. at 406–07.
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the same.50 The following month, the University of Oxford announced it
would begin a new trial of its COVID-19 vaccine in Johannesburg, South
Africa.51 In June 2020, protestors challenged the trials as exploiting
African people as “guinea pigs,” informed by the ongoing disposability
with which their lives are regarded.52
In response, some have stressed the necessity of diversity in clinical
trials in ways that problematically reify biological understandings of race.53
Others have dismissed concerns about the vaccine as irrational in the face
of a public health emergency.54 Yet, the resistance of Black people from
the United States to South Africa must be contextualized against both
present and past experiences with systemic racism. Indeed, the sordid
history of human experimentation carried out on Black and other people
of color has reinforced the disposable nature with which our lives are
regarded: from J. Marion Sims conducting unanesthetized ﬁstula surgeries
on enslaved Black women’s bodies based on the stereotyped belief that
Black people have a high tolerance for pain;55 to the notorious Tuskegee
syphilis experiments, wherein health authorities deliberately failed to treat
and misled 600 Black men about the nature of their care;56 to the
exploitation of Henrietta Lacks in research;57 and to present day issues

50. Lauran Neergaard & Hannah Fingerhut, AP-NORC Poll: Half of Americans Would
Get a COVID-19 Vaccine, AP-NORC (May 27, 2020), https://apnorc.org/ap-norc-poll-halfof-americans-would-get-a-covid-19-vaccine [https://perma.cc/Z76S-2LQL].
51. Trial of Oxford COVID-19 Vaccine in South Africa Begins, Univ. of Oxford (June
23, 2020), https://www.ox.ac.uk/news/2020-06-23-trial-oxford-covid-19-vaccine-south-africabegins [https://perma.cc/7EES-CLR2].
52. ‘We Are Not Guinea Pigs,’ Say South African Anti-Vaccine Protesters, Reuters (July
1, 2020), https://www.reuters.com/article/us-health-coronavirus-safrica-vaccine/we-are-notguinea-pigs-say-south-african-anti-vaccine-protesters-idUSKBN2426RY [https://perma.cc/JBC275HM].
53. Colleen Campbell, Racial Inclusivity in COVID-19 Vaccine Trials, Petrie Flom Ctr.:
Bill of Health (Sept. 22, 2020), https://blog.petrieﬂom.law.harvard.edu/2020/09/22/
racial-inclusivity-covid19-vaccine-trials [https://perma.cc/U3V8-QQNA] (“Recent calls for
racial inclusivity in vaccine trials, which often rely on genetic rationales while emphasizing
medical distrust among African Americans, unfortunately lack an equally robust critique of
medical racism and the ongoing reasons for this distrust.”).
54. Max Boot, Opinion, No Vaccine Can End America’s Pandemic of Ignorance and
Irrationality, Wash. Post (Dec. 22, 2020), https://www.washingtonpost.com/opinions/
2020/12/22/no-vaccine-can-end-americas-pandemic-ignorance-irrationality (on ﬁle with
the Columbia Law Review).
55. Keith Wailoo, Opinion, Historical Aspects of Race and Medicine, The Case of J.
Marion Sims, 320 JAMA 1529, 1529 (2018); see also Durrenda Ojanuga, The Medical Ethics
of the ‘Father of Gynaecology’, Dr J Marion Sims, 19 J. Med. Ethics 28, 29 (1993).
56. Marcella Alsan & Marianne Wanamaker, Tuskegee and the Health of Black Men,
133 Q.J. Econ. 407, 413–14 (2018).
57. Robert D. Truog, Aaron S. Kesselheim & Steven Joffe, Paying Patients for Their
Tissue: The Legacy of Henrietta Lacks, 337 Science 37, 37 (2012).
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with clinical trials that treat Black and other people of color as
disposable.58
This past is very much present, and unethical trials on Black and other
people of color continue to take place on the African continent and elsewhere. For example, in 1996, during the worst ever meningitis outbreak
on the African continent, Pﬁzer conducted a clinical trial in which a
hundred children in Nigeria were given an experimental oral antibiotic
called Trovan, while an additional hundred received Ceftriaxone.59 Five
children died on the former antibiotic and six on the latter.60 Some children allegedly received a dose lower than recommended, “leaving many
children with brain damage, paralysis, or slurred speech.”61 The parents of
the children sued Pﬁzer for failure to obtain informed consent and Pﬁzer
settled the suit with the drug trial victims after a protracted ﬁfteen-year
legal battle.62
Moreover, early research trials conducted in Uganda for an AIDS
vaccine were designed to test the safety of HIV Subtype B—a type most
prevalent in Europe and the Americas.63 HIV has more than ten major
subtypes, which correspond with geographical range;64 Subtype D is the
dominant form in East Africa.65 Thus, the research done in Uganda tested
a vaccine designed to attack a virus subtype not prevalent in Uganda.66
Developers wanted a vaccine for Subtype B of HIV to market to highincome countries in Europe and elsewhere in the Global North.67
58. LaVera M. Crawley, African-American Participation in Clinical Trials: Situating
Trust and Trustworthiness, 93 J. Nat’l Med. Ass’n 14S, 14S (2001) (“Reports on AfricanAmerican attitudes and perspectives toward clinical research suggest that mistrust is a
signiﬁcant barrier in the accrual of minorities in clinical trials.”); Idara L. Udonya, Opinion,
Black People Are Not Your Guinea Pigs, Peak (July 25, 2020), https://the-peak.ca/2020/
07/black-people-are-not-your-guinea-pigs [https://perma.cc/D6YT-NYN9].
59. Jacqui Wise, Pﬁzer Accused of Testing New Drug Without Ethical Approval, 322
BMJ 194, 194 (2001).
60. David Smith, Pﬁzer Pays Out to Nigerian Families of Meningitis Drug Trial Victims,
Guardian (Aug. 12, 2011), https://www.theguardian.com/world/2011/aug/11/pﬁzernigeria-meningitis-drug-compensation [https://perma.cc/AP6A-LTB5].
61. Id.
62. Id.
63. Johanna Tayloe Crane, Scrambling for Africa: AIDS, Expertise, and the Rise of
American Global Health Science 57 (2013).
64. Id.
65. Matthew Hierholzer, R. Ross Graham, I. El Khidir, Sybil Tasker, Magdi Darwish,
Gail D. Chapman, Ademola H. Fagbami, Atef Soliman, Deborah L. Birx, Francine
McCutchan, & Jean K. Carr., HIV Type 1 Strains from East and West Africa Are Intermixed
in Sudan, 18 AIDS Rsch. & Hum. Retroviruses 1163, 1164 (2002).
66. José Esparza, A Brief History of the Global Effort to Develop a Preventive HIV
Vaccine, 31 Vaccine 3502, 3505 (2013); see also Crane, supra note 63, at 70–72 & n.7.
67. See Crane, supra note 63, at 54–80 (“The uptake of subtype B viruses as the basis
for HIV laboratory research and technology development was not random, but reﬂects the
fact that the great majority of both research funding and infrastructure are located squarely
in the United States and Western Europe, where subtype B predominates.”).
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Boehringer Ingelheim also supported suspect clinical trials in Uganda
between 1997 and 2003 that led to thousands of serious adverse effects for
women taking the anti-HIV transmission drug Nevirapine.68 Their
symptoms went unreported, but testing continued and resulted in the
deaths of fourteen of these women.69
Furthermore, during the 2014–2016 Ebola outbreak, an Italian NGO
tested the heart drug Amiodarone on Ebola patients at a treatment facility
in Sierra Leone.70 The drug is not among the ﬁfty-three drugs listed to
have an antiviral effect on Ebola.71 Some British medics working at the
center concluded that the side effects from the drug could be contributing
to the increased morbidity within the center.72 Certain medical staff staged
a walk-out from the facility to protest the use of the drug outside of a
clinical trial concomitant with the lack of informed consent obtained from
patients.73 Some researchers also took thousands of blood samples from
Ebola patients during the 2014–2016 epidemic and now hold these
samples in secretive laboratories around the world.74 Ebola survivors did
not consent to their blood being used for research.75 Several African
scientists accused the laboratories of “biological asset stripping,” as the
scientists are unable to access the samples for their own research despite
African health practitioners assuming all the risk in drawing the blood.76

68. Efe Egharevba & Jacqueline Atkinson, The Role of Corruption and Unethical
Behaviour in Precluding the Placement of Industry Sponsored Clinical Trials in SubSaharan Africa: Stakeholder Views, 3 Contemp. Clin. Trials Commc’ns 102, 103 (2016).
69. Francis Weyzig & Irene Schipper, SOMO Brieﬁng Paper on Ethics in Clinical Trials
6 (2008), https://www.somo.nl/wp-content/uploads/2008/02/Examples-of-unethicaltrials.pdf (on ﬁle with the Columbia Law Review).
70. Philippe Calain, The Ebola Clinical Trials: A Precedent for Research Ethics in
Disasters, 44 J. Med. Ethics 3, 5 (2016); Fabio Turone, Doctors Trial Amiodarone for Ebola
in Sierra Leone, 349 BMJ 7198, 7198 (2014).
71. Jennifer Kouznetsova, Wei Sun, Carles Martínez-Romero, Gregory Tawa, Paul
Shinn, Catherine Z Chen, Aaron Schimmer, Philip Sanderson, John C McKew, Wei Zheng
& Adolfo García-Sastre, Identiﬁcation of 53 Compounds that Block Ebola Virus-Like Particle
Entry Via a Repurposing Screen of Approved Drugs, 3 Emerging Microbes & Infections 1,
4–7 (2014); see also Study Identiﬁes 53 Approved Drugs that May Block Ebola, Infection
Control Today (Dec. 17, 2014), https://www.infectioncontroltoday.com/view/studyidentiﬁes-53-approved-drugs-may-block-ebola-infection [https://perma.cc/76P3-6CTY].
72. Sarah Boseley, Untested Ebola Drug Given to Patients in Sierra Leone Causes U.K.
Walkout, Guardian (Dec. 22, 2014), https://www.theguardian.com/world/2014/dec/22/
ebola-untested-drug-patients-sierra-leone-uk-staff-leave [https://perma.cc/Z24M-TFW9].
73. Id.
74. Maryn McKenna, Colonialists Are Coming for Blood—Literally, WIRED (Mar. 3,
2019), https://www.wired.com/story/ebola-epidemic-blood-samples [https://perma.cc/
M7MB-45A3].
75. Id.
76. Emmanuel Freudenthal, Ebola’s Lost Blood: Row over Samples Flown Out of Africa
as ‘Big Pharma’ Set to Cash In, Telegraph (Feb. 6, 2019), https://www.telegraph.co.uk/globalhealth/science-and-disease/ebolas-lost-blood-row-samples-flown-africa-big-pharma-set-cash
[https://perma.cc/VC4D-Y8ZA].
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These incidents are clear violations of established research guidelines,
reﬂected in the World Medical Association’s Declaration of Helsinki and
the WHO’s Handbook for Good Clinical Research Practice. Furthermore,
they indicate the limitations of the guidelines’ ability to protect the rights
and welfare of Black and other people of color.77 Moreover, even where
legal and regulatory frameworks exist on paper for study participants, the
de facto policy of treating Black, Indigenous, and other people of color as
disposable requires more robust mechanisms to counteract the praxis of
dehumanization. Accordingly, the unethical treatment and exploitation of
subordinated groups informs the hesitancy of some to participate in
clinical trials and to sign up for the COVID-19 vaccines authorized for
emergency use.
IV. DISPOSABLE LIVES AND ACCESS TO VACCINES
Importantly, however, the turn to “vaccine hesitancy” to account for
the gross disparities in the distribution of the COVID-19 vaccines obscures
structural, legal, and policy barriers to access. For example, vaccine
redlining policies have located many distribution centers outside of
communities of color in the United States. Indeed, officials in Dallas
County had to stop a plan prioritizing COVID-19 vaccine doses for people
living in the most vulnerable zip codes after the state of Texas threatened
to cut off the county’s vaccine supply.78 Moreover, preliminary data from
states that track vaccination data by race indicate that COVID-19 vaccines
are primarily going to White people, despite the fact that the pandemic is
ravaging communities of color disproportionately.79 Commentators
77. See WMA Declaration of Helsinki—Ethical Principles for Medical Research
Involving Human Subjects, World Med. Ass’n (July 9, 2018), https://www.wma.net/policiespost/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-humansubjects [https://perma.cc/A327-PKEV] (“Physicians must consider the ethical, legal and
regulatory norms and standards for research involving human subjects in their own
countries as well as applicable international norms and standards.”); WHO, Handbook for
Good Clinical Research Practice (GCP): Guidance for Implementation 19 (2005),
https://apps.who.int/iris/bitstream/handle/10665/43392/924159392X_eng.pdf
[https://perma.cc/U9VM-KAZ2] (“[T]he most important considerations are those related
to the rights, safety, and well-being of the research subjects.”).
78. Emma Platoff & Juan Pablo Garnham, Dallas County Axes Plan to Prioritize
Vaccinating Communities of Color After State Threatens to Slash Allocation, Tex. Trib.
(Jan. 20, 2021), https://www.texastribune.org/2021/01/20/dallas-vaccine-plan-communitiesof-color [https://perma.cc/93UE-Y4SR].
79. See, e.g., COVID-19 Vaccines, NYC Health, https://www1.nyc.gov/site/doh/
covid/covid-19-data-vaccines.page [https://perma.cc/J787-YC9D] (last visited Feb. 27,
2021) (providing data on adults that were vaccinated with at least one dose and where race
was indicated); see also Shelby Livingston, Most COVID-19 Vaccines Are Going to White
People, Even Though the Pandemic Has Ravaged Communities of Color, Bus. Insider (Jan.
8, 2021), https://www.businessinsider.com/covid-shots-given-to-white-people-state-vaccinedata-2021-1 [https://perma.cc/G6U6-52JQ]; Amy Schoenfeld Walker, Anjali Singhvi, Josh
Holder, Robert Gebeloff & Yuriria Avila, Pandemic’s Racial Disparities Persist in Vaccine
Rollout, N.Y. Times (Mar. 5, 2021), https://www.nytimes.com/interactive/2021/03/05/
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developed the concept of vaccine apartheid to capture the nature of these
stark inequities.80
Vaccine apartheid is similarly glaring when examining access to
vaccines internationally. Globally, vaccine redlining has meant that people
living in many countries in the Global South are not expected to have
signiﬁcant doses of vaccines administered until as late as 2024.81 Some of
this delay is the result of limited supply, lack of production facilities, and
logistical impediments, such as the need for vaccine storage at subzero
temperatures requiring the development of a cold distribution chain for
vaccine administration.82 Moreover, international solidarity has been
wanting; instead, vaccine nationalism has predominated, with some
countries prioritizing and competing for bilateral deals and hoarding
enough supplies to vaccinate their populations several times over.83
Indeed, some analyses indicate that rich countries are on track to hoard
over one billion COVID-19 vaccines.84 Further, the European Union

us/vaccine-racial-disparities.html (on ﬁle with the Columbia Law Review); Only One U.S.
State Has Vaccinated 10% of Its Black Population: COVID-19 Tracker, Bloomberg (Feb. 24,
2021), https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/
us-vaccine-demographics.html (on ﬁle with the Columbia Law Review).
80. See, e.g., Winnie Byanyima, A Global Vaccine Apartheid Is Unfolding. People’s
Lives Must Come Before Proﬁt, Guardian (Jan. 29, 2021), https://www.theguardian.com/
global-development/2021/jan/29/a-global-vaccine-apartheid-is-unfolding-peoples-livesmust-come-before-proﬁt [https://perma.cc/YEN9-NCW2].
81. See Francesco Guarascio, WHO Vaccine Scheme Risks Failure, Leaving Poor
Countries with No COVID Shots Until 2024, Reuters (Dec. 16, 2020), https://reuters.com/
article/amp/idUSKBN28Q1LF (on ﬁle with the Columbia Law Review).
82. Michaeleen Doucleff, Why Poorer Countries Aren’t Likely to Get the Pﬁzer
Vaccine Any Time Soon, NPR Ill. (Nov. 11, 2020), https://www.nprillinois.org/post/whypoorer-countries-arent-likely-get-pﬁzer-vaccine-any-time-soon#stream/0
[https://perma.cc/3TC2-XNWV].
83. Peter S. Goodman, One Vaccine Side Effect: Global Economic Inequality, N.Y.
Times (Dec. 25, 2020), https://www.nytimes.com/2020/12/25/business/coronavirusvaccines-global-economy.html (on ﬁle with the Columbia Law Review) (last updated Dec. 31,
2020) (“Wealthy nations in Europe and North America have secured the bulk of limited
stocks of vaccines . . . . Developing countries—home to most of humanity—are left to secure
their own doses.”); Rich Countries Hoarding COVID Vaccines, Says People’s Vaccine
Alliance, BBC News (Dec. 9, 2020), https://www.bbc.co.uk/news/amp/health-55229894
[https://perma.cc/QR3L-7MNS] [hereinafter Rich Countries Hoarding COVID Vaccines]
(describing a study that found that “rich countries have bought enough doses to vaccinate
their entire populations three times over if all the vaccines are approved for use”); WHO
Director-General’s Opening Remarks at 148th Session of the Executive Board, WHO (Jan.
18, 2021), https://www.who.int/director-general/speeches/detail/who-director-general-sopening-remarks-at-148th-session-of-the-executive-board [https://perma.cc/K9AW-3CDN]
(“Even as they speak the language of equitable access, some countries and companies
continue to prioritize bilateral deals, going around COVAX, driving up prices and
attempting to jump to the front of the queue.”).
84. See, e.g., ONE, Rich Countries on Track to Stockpile over 1 Billion Surplus C19
Vaccines 1 (2021), https://s3.amazonaws.com/one.org/pdfs/ONE_Analysis_on_excess_
doses.pdf [https://perma.cc/BB63-S9G8].
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authorized its member states to put limitations on the exportation of
vaccines.85
Concomitantly, wealthy countries have failed to adequately support
and fund global health schemes like COVAX,86 which is the main initiative
of the WHO to provide COVID-19 vaccinations to people in low- and
middle-income countries.87 COVAX requires ﬁnancial contributions and
donations from wealthy countries to work.88 Yet, it is unseemly and unjust
for wealthy countries to hoard vaccines and drive up prices on the one
hand, which makes it difficult for other countries to acquire vaccines,
while also promising charitable donations that are insufficient. Further,
even if the COVAX initiative were fully funded, a philanthropic model that
relies on the muniﬁcence of others to donate money or share vaccine
surpluses is fundamentally ﬂawed, given the need for countries to
vaccinate entire populations. In late February 2021, Ghana became the
ﬁrst country to receive vaccine doses under this scheme.89 Yet, the late
“timing and the relatively modest supply—enough for just 1% of Ghana’s
population—point to major challenges”90 moving forward. Indeed, by
April 2021, COVAX “distributed 43 million doses of vaccine to 119
countries—covering just 0.5 percent of their combined population of
more than four billion.”91 Additionally, as detailed below, an artiﬁcially
limited supply of vaccines is caused by Big Pharma’s monopoly on prices
and proﬁt, which exacerbates inequities and results in more restricted or
delayed vaccine access for many countries in the Global South. Moreover,
COVAX depends on extant power relations that are skewed in favor of the

85. Obiora Chinedu Okafor & James Thuo Gathii, The EU’s Vaccine Export Controls
Negate Its Self-Interest, International Solidarity and International Law, Afronomics L. (Feb.
18, 2021), https://www.afronomicslaw.org/category/analysis/eus-vaccine-export-controlsnegate-its-self-interest-international-solidarity-and [https://perma.cc/5KNN-XGNB] (discussing the EU’s binding regulations that authorize member states “to limit the export of
COVID-19 vaccines produced within its borders”).
86. See, e.g., Anna Rouw, Jennifer Kates, Josh Michaud & Adam Wexler, COVAX and
the United States, Kaiser Fam. Found. (Feb. 18, 2021), https://www.kff.org/coronaviruscovid-19/issue-brief/covax-and-the-united-states [https://perma.cc/6ZMS-R2FA] (discussing
funding and regulatory challenges with COVAX).
87. COVAX: Working for Global Equitable Access to COVID-19 Vaccines, WHO,
https://www.who.int/initiatives/act-accelerator/covax [https://perma.cc/C9V7-2CBX] (last
visited Feb. 13, 2021).
88. Rouw et al., supra note 86 (“COVAX has an overall funding target (2020–2021) of
$11.1 billion but faces a $7.2 billion funding gap. Given the economic crisis that has gripped
much of the world due to COVID-19, it is not yet clear how this gap can be ﬁlled.”).
89. Danielle Paquette & Emily Rauhala, First Vaccine Doses Distributed by Covax Land in
West African Nation of Ghana, Wash. Post. (Feb. 24, 2021), https://www.washingtonpost.com/
world/africa/covax-ghana-astrazeneca-vaccine/2021/02/24/558d31bc-7617-11eb-94898f7dacd51e75_story.html (on file with the Columbia Law Review).
90. Id.
91. Tedros Adhanom Ghebreyesus, Opinion, I Run the W.H.O., and I Know that Rich
Countries Must Make a Choice, N.Y. Times (Apr. 22, 2021), https://www.nytimes.com/
2021/04/22/opinion/who-covid-vaccines.html (on ﬁle with the Columbia Law Review).
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pharmaceutical industry and countries where the production of vaccine
doses takes place.
South Africa is a prime case study of vaccine apartheid, as it is one of
the ﬁrst countries on the African continent to procure a vaccine and is also
one of the hardest hit by the pandemic.92 Notably, the Oxford–
AstraZeneca vaccine, the trials for which were greeted with protests in
Johannesburg,93 has an increasingly uncertain future in South Africa and
beyond.94 The Oxford–AstraZeneca vaccine was supposed to be used
widely in countries in the Global South, as the manufacturer projected
that it could quickly produce billions of doses.95 This supply is substantially
greater and at a signiﬁcantly lower price than any of the other vaccines
shown to offer protection against COVID-19.96
Recalling the concept of medical neocolonialism is instructive here,
as South Africa obtained millions of vaccine doses at a cost of $5.25 per
dose, which is more than double the $2.16 per dose that European Union
countries paid to AstraZeneca.97 Moreover, since South Africans initially
participated in clinical trials for the development of the drug, they should
have had greater post-trial access and beneﬁt-sharing based on fundamental principles of research referenced earlier.98 Instead, South Africa had to
92. See Keymanthri Moodley & Theresa Rossouw, South African COVID-19 Vaccine
Trials Hold Key Lessons for Future Partnerships, Conversation (Feb. 9, 2021),
https://theconversation.com/south-african-covid-19-vaccine-trials-hold-key-lessons-forfuture-partnerships-154676 [https://perma.cc/42C7-YVHU].
93. See supra note 52 and accompanying text. Initially, the University of Oxford
promised to donate the rights to its vaccine but then reneged on this promise by selling the
sole rights to the producer AstraZeneca. Jay Hancock, They Pledged to Donate Rights to
Their COVID Vaccine, Then Sold Them to Pharma, KHN (Aug. 25, 2020),
https://khn.org/news/rather-than-give-away-its-covid-vaccine-oxford-makes-a-deal-withdrugmaker [https://perma.cc/4J8N-W6DW].
94. See Robert Hart, Expert Panel Calls on Norway to Ditch AstraZeneca and Johnson
& Johnson COVID Vaccines over Blood Clot Risks, Forbes (May 10, 2021),
https://www.forbes.com/sites/roberthart/2021/05/10/expert-panel-calls-on-norway-toditch-astrazeneca-and-johnson--johnson-covid-vaccines-over-blood-clot-risks
[https://perma.cc/4BQU-2CVS]; see also Lisa Schnirring, More Global Reports of Blood
Clots After AstraZeneca COVID Vaccination, CIDRAP: Ctr. for Infectious Disease Rsch. &
Pol’y (Apr. 2, 2021), https://www.cidrap.umn.edu/news-perspective/2021/04/more-globalreports-blood-clots-after-astrazeneca-covid-vaccination [https://perma.cc/SXD2-KWKV].
95. Jon Cohen, South Africa Suspends Use of AstraZeneca’s COVID-19 Vaccine After
It Fails to Clearly Stop Virus Variant, Science (Feb. 8, 2021), https://www.sciencemag.org/
news/2021/02/south-africa-suspends-use-astrazenecas-covid-19-vaccine-after-it-fails-clearlystop [https://perma.cc/9MC4-554A].
96. See Rich Countries Hoarding COVID Vaccines, supra note 83.
97. Helen Sullivan, South Africa Paying More than Double EU Price for Oxford
Vaccine, Guardian (Jan. 22, 2021), https://www.theguardian.com/world/2021/jan/22/
south-africa-paying-more-than-double-eu-price-for-oxford-astrazeneca-vaccine
[https://perma.cc/8MRG-8YQ2]; see also Moodley & Rossouw, supra note 92.
98. See Hae Lin Cho, Marion Danis & Christine Grady, Post-Trial Responsibilities
Beyond Post-Trial Access, 391 Lancet 1478, 1478–79 (2018) (“[P]ost-trial care is necessary
to prevent the exploitation of participants with insufficient access to health care . . . .”); D.
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pay more for a drug it ultimately will not be able to use. The trial of the
vaccine revealed comparatively low efficacy rates (under 25%) against mild
and moderate cases of the disease in South Africa, a threshold that does
not “meet minimal international standards for emergency use.”99 South
Africa has discontinued its plans to use the AstraZeneca vaccine, given the
vaccine’s ineffectualness against a newer variant of the virus that is prevalent in South Africa.100 At the time of writing, its national immunization
drive is in ﬂux. This is compounded by Moderna’s (manufacturer of one
of the most expensive COVID-19 vaccines101) earlier indication that it did
not plan to distribute its vaccine in South Africa.102 Signiﬁcantly, a single
dose of the Moderna vaccine costs approximately $32–$37 and has an
efficacy of approximately 95%.103 While Moderna pledged not to enforce
its patent during the COVID-19 pandemic,104 it does not own all the
patents in its vaccine.105 Accordingly, Moderna cannot make credible
commitments that bind other patentholders.
Conventional analyses would simply treat vaccine apartheid as driven
by and fully accounted for by poverty. Such shallow analyses, however, tend
to obscure the functioning of race and histories of subordination, which is
why the concept of medical neocolonialism is so useful. The South African
example vividly illustrates how “the fruits of medical and scientiﬁc
advances are stockpiled for some and denied for others.”106 By failing to
Schroeder, Beneﬁt Sharing: It’s Time for a Deﬁnition, 33 J. Med. Ethics 205, 207 (2007)
(“Beneﬁt sharing is the action of giving a portion of advantages/proﬁts derived from the
use of human genetic resources to the resource providers in order to achieve justice in
exchange with particular emphasis on the clear provision of beneﬁts to those who may lack
reasonable access to resulting products . . . .”); see also supra note 77.
99. Cohen, supra note 95.
100. Id.
101. Rich Countries Hoarding COVID Vaccines, supra note 83.
102. Geoffrey York, COVID-19 Vaccine Supplies for Africa Dwindling as Moderna Opts
Out, Globe & Mail (Jan. 3, 2021), https://www.theglobeandmail.com/amp/world/articlevaccine-supplies-for-africa-dwindling-as-moderna-opts-out [https://perma.cc/AGY3-DKAT].
103. Sissi Cao, COVID-19 Vaccine Prices Revealed from Pﬁzer, Moderna, and
AstraZeneca, Observer (Nov. 23, 2020), https://observer.com/2020/11/covid19-vaccineprice-pfizer-moderna-astrazeneca-oxford [https://perma.cc/S6P7-VEEF]; Berkeley Lovelace
Jr., Moderna Is Pricing Coronavirus Vaccine at $32 to $37 Per Dose for Some Customers,
CNBC (Aug. 5, 2020), https://www.cnbc.com/2020/08/05/moderna-is-pricing-coronavirusvaccine-at-32-to-37-per-dose-for-some-customers.html [https://perma.cc/VP8Y-7VQV].
104. Statement by Moderna on Intellectual Property Matters During the COVID-19
Pandemic, Moderna (Oct. 8, 2020), https://investors.modernatx.com/news-releases/newsrelease-details/statement-moderna-intellectual-property-matters-during-covid-19
[https://perma.cc/MD43-J8U2].
105. See, e.g., Arthur Allen, Government-Funded Scientists Laid the Groundwork for
Billion-Dollar Vaccines, KHN (Nov. 18, 2020), https://khn.org/news/vaccine-pioneers-basicresearch-scientists-laid-groundwork-for-billion-dollar-pharma-products [https://perma.cc/GJ38YXSF] (discussing how the University of Pennsylvania sublicensed the RNA modiﬁcation
patent to Cellscript who then sublicensed it to Moderna).
106. Paul Farmer, Pathologies of Power: Rethinking Health and Human Rights, 89 Am.
J. Pub. Health 1486, 1488 (1999).
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take an intersectional approach, traditional analyses may not fully capture
how multiple overlapping areas such as race, class, and geography may
function to produce heightened subordination. The political economy
explanation also does not consider how market failures for
pharmaceuticals aimed at diseases that disproportionately impact people
of color are tied to long histories of exploitation, dispossession, and
devaluation of the lives of Black, Indigenous, and other people of color.
A thorough analysis of COVID-19 vaccine apartheid and disposability
must also consider the role of the international intellectual property
regime in severely compounding the challenges of equitable vaccine
distribution. Brieﬂy, the international intellectual property regime
provides a twenty-year monopoly for pharmaceuticals.107 Until the creation
of this regime, many countries did not even place patent protection on
pharmaceuticals. Previously, states regarded patent rights as a national
prerogative rather than a minimum international substantive regime with
standards for what intellectual property rights protections countries
should adopt. Recognizing this, the Trade-Related Aspects of Intellectual
Property Rights (TRIPS) Agreement grants extra implementation time to
developing countries and delayed implementation for the least-developed
countries.108
Although the DOHA Declaration, which reaffirms the TRIPS
Agreement, and some TRIPS provisions were meant to create better ﬂexibilities for public health or incentivize research and development, they
have had limited effect in facilitating access to medicines,109 given the

107. See Agreement on Trade-Related Aspects of Intellectual Property Rights art. 33,
Apr. 15, 1994, 1869 U.N.T.S. 299 [hereinafter TRIPS Agreement] (“The term of protection
available [for patents] shall not end before the expiration of a period of twenty years
counted from the ﬁling date.”).
108. Id. art. 66(1)–66(2).
109. See, e.g., id., art. 31 (authorizing compulsory licensing). The Doha Declaration
looked to clarify that the TRIPS Agreement does not and should not prevent members from
taking measures to protect public health, and that it should be interpreted as compatible in
a manner that promotes access to medicines. World Trade Organization, Ministerial
Declaration on the TRIPS Agreement and Public Health of 14 November 2001 ¶ 4, WTO
Doc. WT/MIN(01)/DEC/2, 41 ILM 755 (2002) [hereinafter Doha Declaration]. The
TRIPS Agreement also seeks to bind developed countries to provide incentives to
“enterprises and institutions in their territories” for technology transfer to developing
countries to “enable them to create a sound and viable technological base.” TRIPS
Agreement, supra note 107, art. 66(2). Additionally, the Doha Declaration tries to reaffirm
the commitment of countries in the Global North to provide incentives to corporations and
other institutions to promote and encourage technology transfer to countries in the Global
South. See Doha Declaration, supra, ¶ 7. For further discussion, see Report of the United
Nations Secretary-General’s High-Level Panel on Access to Medicines: Promoting Innovation
and Access to Health Technologies 23–27 (2016), http://www.unsgaccessmeds.org/s/UNSGHLP-Report-FINAL-12-Sept-2016.pdf [https://perma.cc/QQ9C-6SFR] [hereinafter U.N.
High-Level Panel on Access to Medicines] (discussing the mixed results of the compulsory
licensing provisions and limited utility of other TRIPS ﬂexibilities).
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larger incentive structure toward proﬁt maximization.110 Indeed, the
creation of the international intellectual property regime and the
ratiﬁcation of this regime in the Doha Declaration has functioned to
expand and increase U.S.-style pharmaceutical patent protection
globally.111 Further, the United States often threatens to close off its
market to countries that run afoul of its interpretation of what the TRIPS
regime requires for protecting pharmaceuticals.112 The United States and
others also advance their structural power against states in the Global
South through a mix of TRIPS-plus provisions placed in bilateral and
regional free-trade agreements that have imposed much more stringent
requirements on countries than required by TRIPS.113

110. For example, EpiPen’s original marketing approval occurred on December 22,
1987. See Drugs@FDA: FDA Approved Drug Products, New Drug Application (NDA):
019430, FDA, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview
.process&ApplNo=019430 [https://perma.cc/54YP-W2GT] (last visited Feb. 14, 2021).
Mylan, a global pharmaceutical company, acquired the rights to make and sell EpiPen,
which sold in 2007 for approximately $100 for a two-pen set. Tara Parker-Pope & Rachel
Rabkin Peachman, EpiPen Price Rise Sparks Concern for Allergy Sufferers, N.Y. Times: Well
(Aug. 22, 2016), https://well.blogs.nytimes.com/2016/08/22/epipen-price-rise-sparksconcern-for-allergy-sufferers (on ﬁle with the Columbia Law Review). Mylan used its market
power to raise the price of the two-pen set to exceed $600, raising their sales from over $200
million annually to over $1 billion. Andrew Pollack, Mylan Raised EpiPen’s Price Before the
Expected Arrival of a Generic, N.Y. Times (Aug. 24, 2016), https://www.nytimes.com/2016/
08/25/business/mylan-raised-epipens-price-before-the-expected-arrival-of-a-generic.html (on
ﬁle with the Columbia Law Review). Given that EpiPens expire after a year, the price hike put
a huge strain on patients’ ability to afford this life-saving medicine. Parker-Pope &
Peachman, supra.
111. See James Thuo Gathii, Construing Intellectual Property Rights and Competition
Policy Consistently with Facilitating Access to Affordable Aids Drugs to Low-End Consumers,
53 Fla. L. Rev. 727, 754–59 (2001) (discussing the shift in U.S. trade policy in the 1980s to
focus on the production and transformation of conceptual notions into intangible ﬂows of
idea and money). This led to a concerted policy toward enhancing the protection of U.S.
intellectual property rights globally and culminated in the TRIPS Agreement. Id. Notably,
the Doha Declaration continues to affirm the importance of patent protection. Doha
Declaration, supra note 109, ¶ 5, ¶ 7.
112. Section 301 authorizes the use of unilateral trade sanctions as a retaliatory measure
by the United States. U.S. Trade Act of 1974, Pub. L. No. 93-618, § 301, 88 Stat. 1978, 2041
(codiﬁed at 19 U.S.C. § 2411 (2018)). The United States removed South Africa from its
watch list following advocacy by HIV/AIDS organizations. See, e.g., Press Release, Off. of
the U.S. Trade Rep., U.S.–South Africa Understanding on Intellectual Property (Sept. 17,
1999), https://web.archive.org/web/20001030065239/https://ustr.gov/releases/1999/
09/99-76.html (on ﬁle with the Columbia Law Review). For further discussion, see Rosalyn S.
Park, Note, The International Drug Industry: What the Future Holds for South Africa’s
HIV/AIDS Patients, 11 Minn. J. Global Trade 125, 136–39 (2002); see also Exec. Order No.
13,155, 65 Fed. Reg. 30,521, 30,522 (May 12, 2000) (noting that the United States would not
seek the revocation or revision of any intellectual property law in sub-Saharan African
nations, so long as they promote access to HIV/AIDS treatment, and requiring sub-Saharan
African countries to provide intellectual property protection as a precondition for
increasing access to HIV/AIDS drugs).
113. U.N. High-Level Panel on Access to Medicines, supra note 109, at 25–26 (table with
sample TRIPS-plus provisions).
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Conventional wisdom holds that pharmaceutical companies depend
on charging monopoly prices to recover their investments in experimental
drugs and technologies.114 Yet, there are well-established arguments that a
market-based monopoly incentive for pharmaceuticals is ill-suited for
addressing health needs.115 Commentators have artfully pointed out the
severe limitations of a research and innovation system based on monopoly
rights.116 Such a system tends to focus research and development efforts
toward “lucrative” medical conditions that pose minimal risks and toward
ailments that already have existing effective therapies.117 This incentive
system allows many pharmaceutical corporations to beneﬁt substantially
from publicly funded research and still charge monopoly prices. Overall,
the intellectual property regime shelters corporations from competition,
enables them to increase prices, underproduces certain drugs, cuts back
on product quality, and declines to produce some pharmaceuticals.118
Vaccines in particular have been deprioritized by the pharmaceutical
industry as insufficiently proﬁtable. This was the case with the Ebola virus,
114. See Ingo Venzke, International Law and the Spectre of Inequality 8 (2019),
http://cf.bc.uva.nl/download/oraties/oraties_2019/Venzke_Ingo.pdf [https://perma.cc/
826J-HWBB].
115. See Yaniv Heled, Liza Vertinsky & Cass Brewer, Why Healthcare Companies Should
Be(come) Beneﬁt Corporations, 60 B.C. L. Rev. 73, 107 (2019) (discussing how the failure
of price to serve as a good indicator of public health value, the public sharing of costs but
not beneﬁts, and the regulation and market structure that limit competition often produce
poor public health outcomes); see also Debora J. Halbert, Resisting Intellectual Property 4
(2005) (“In addition to the negative consequences of patenting the inventions derived from
the human body, pharmaceutical companies have placed proﬁts before lives as they
aggressively litigate to halt the unauthorized production of drugs used to ﬁght HIV and
AIDS.”); Kaushik Sunder Rajan, Pharmocracy: Value, Politics, and Knowledge in Global
Biomedicine 37 (2017) (“[L]ogics of capital grounded in the generation of surplus lead to
a structure of crisis in global pharmaceutical industries, leading to trials for the industry
itself, for patients and consumers who constitute its markets, and for populations who are
excluded from these markets.”); Madhavi Sunder, From Goods to a Good Life: Intellectual
Property and Global Justice 175–77 (2012) (“[T]he exclusive patent right allows a monopoly
on the production of the drug, which generally leads to higher prices for the cure.”);
Margaret Chon, Intellectual Property and the Development Divide, 27 Cardozo L. Rev.
2821, 2891 (2006) (“The inequitable nature of technical knowledge production and
capacity-building relevant to developing countries is starkly illustrated by health care
research and development.”); Venzke, supra note 114, at 8 (discussing how there “is now a
growing consensus across disciplines that such protection has gone too far, stiﬂing rather
than sparking innovation, and transferring rather than creating value”).
116. See Keith Aoki, Space Invaders: Critical Geography, The “Third World” in
International Law and Critical Race Theory, 45 Vill. L. Rev. 913, 930 (2000) (discussing the
problems of transplanting U.S. and European intellectual property regimes to countries in
the developing world and expecting comparable results); Anjali Vats & Deidre A. Keller,
Critical Race IP, 36 Cardozo Arts & Ent. L.J. 735, 738 (2018) (discussing the interdisciplinary
movement of scholars connected by their focus on the racial and colonial non-neutrality of
intellectual property laws).
117. Heled et al., supra note 115, at 84.
118. See, e.g., id. at 118 n.198 (discussing studies that show the impact of price
concentration).
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which ﬁrst appeared in 1976.119 Until the West African Ebola outbreak in
2014, no approved vaccine existed,120 resulting in fatal and devastating
consequences for many.121 The swift development of the COVID-19
vaccines was the result of work done in academic labs with public funding
and beneﬁtted from the signiﬁcant ﬁnancial investment by wealthy
governments that negotiated massive buyout contracts relying on money
from taxpayers.122 As discussed above, wealthier countries rushed to outbid
each other to secure vaccines from a limited supply. Yet, there is an
insufficient supply of vaccines in part because pharmaceutical companies
exercise their monopoly power to prevent others from accessing the
publicly funded technologies needed to create the vaccines. For example,
in 2020, the WHO created a technology access pool to encourage
pharmaceutical companies to share their knowledge with manufacturers
in other countries that need to develop vaccines, but not one company has
done so at the time of writing.123
Against this background, in October 2020, India and South Africa
requested that the Council for TRIPS recommend a waiver from the
implementation, application, and enforcement of certain provisions of the
TRIPS Agreement.124 They argued that a waiver was needed to prevent,
contain, and treat COVID-19, given the acute health shortages faced by
119. Ebola Virus Disease, WHO (Feb. 23, 2021), http://www.who.int/news-room/factsheets/detail/ebola-virus-disease [https://perma.cc/T9FF-WZY9].
120. See, e.g., Janice E. Graham, Ebola Vaccine Innovation: A Case Study of
Pseudoscapes in Global Health, 29 Critical Pub. Health 401, 401, 408 (2019) (discussing
how an international platform was created to accelerate testing of existing experimental
Ebola vaccines due to the WHO’s declaration of a public health emergency).
121. Id. at 401, 405.
122. See Matthew D. Shin, Sourabh Shukla, Young Hun Chung , Veronique Beiss, Soo
Khim Chan, Oscar A. Ortega-Rivera , David M. Wirth , Angela Chen, Markus Sack, Jonathan
K. Pokorski & Nicole F. Steinmetz, COVID-19 Vaccine Development and a Potential
Nanomaterial Path Forward, 15 Nature Nanotechnology 646, 651–52 (2020); Ognian
Kassabov, Opinion, What the Vaccine Debacle Tells Us About Predatory Capitalism, Al
Jazeera (Feb. 21, 2021), https://www.aljazeera.com/opinions/2021/2/21/the-vaccinedebacle-shows-the-predatory-nature-of-capitalism [https://perma.cc/AFZ5-P3NU].
123. See COVID-19 Technology Access Pool, WHO, https://www.who.int/initiatives/
covid-19-technology-access-pool [https://perma.cc/6R3X-V3PU] (last visited May 18, 2021)
(inviting “[h]olders of COVID-19 health technology related knowledge, intellectual property and/or data . . . to join the Solidarity Call to Action NOW!”). Yet, no pharmaceutical
companies are listed under endorsements of the call to action. See Endorsements of the
Solidarity Call to Action, WHO, https://www.who.int/initiatives/covid-19-technology-accesspool/endorsements-of-the-solidarity-call-to-action [https://perma.cc/Q4PA-63ND] (last
visited May 18, 2021); see also Selam Gebrekidan & Matt Apuzzo, Rich Countries Signed Away
a Chance to Vaccinate the World, N.Y. Times (Mar. 21, 2021), https://www.nytimes.com/2021/
03/21/world/vaccine-patents-us-eu.html (on ﬁle with the Columbia Law Review) (last updated
May 7, 2021).
124. Thiru Balasubramaniam, WTO TRIPS Council: India and South Africa Submit
Draft Decision Text on a Waiver from Certain Provisions of the TRIPS Agreement for the
Prevention, Containment and Treatment of COVID-19, Knowledge Ecology Int’l (Oct. 2,
2020), https://www.keionline.org/34061 [https://perma.cc/28VN-9AD3].
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many countries. India and South Africa requested that the “waiver should
continue in effect until widespread vaccination is in place globally, and the
majority of the world’s population has developed immunity.”125 Changing
the incentive structures for the research and development of drugs,
including suspending the application of trade-related intellectual property
rights to essential drugs for lower-income countries, has been proposed
before.126 Notably, the UN’s High-Level Panel on Access to Medicines has
not gone as far, but its recommendations recognize the need to alter the
legal environment such that international treaties improve, rather than
hinder, access to innovation.127
India and South Africa’s joint submission seeks to substantially
reshape the TRIPS regime by allowing for deep technology transfer for
effective COVID-19 vaccines, therapeutics, and diagnostic tests. The joint
submission is wide-ranging and covers not only patents, but also copyright,
industrial designs, and undisclosed information including know-how and
trade secrets.128 The purpose of the temporary ban would be to allow multiple actors to start production, instead of limiting manufacturing to the
small number of current patent-holders, which limits access and renders
signiﬁcant numbers of people disposable. The proposal has found support
from the African group of countries and other developing countries at the
World Trade Organization.129 In May 2021, the Biden Administration
indicated that “[t]he US supports the waiver of IP protections on COVID19 vaccines to help end the pandemic and we’ll actively participate in . . .
125. Thiru Balasubramaniam, WTO TRIPS Council (October 2020): South Africa Issues
Clarion Call Urging Support for TRIPS Waiver Proposal, Knowledge Ecology Int’l (Oct. 16,
2020), https://www.keionline.org/34235 [https://perma.cc/6NSX-ZLYE].
126. For further discussion, see, e.g., Lisa Forman, The Inadequate Global Policy
Response to Trade-Related Intellectual Property Rights: Impact on Access to Medicines in
Low- and Middle-Income Countries, 31 Md. J. Int’l L. 8, 19 (2017) (“As a case in point, the
2012 U.N. Commission on HIV and the Law recommended that WTO members urgently
suspend TRIPS for essential drugs for low- and middle-income countries, and that the U.N.
Secretary General convene a new body to recommend a new intellectual property regime
for drugs.”).
127. U.N. High-Level Panel on Access to Medicines, supra note 109, at 26–27 (noting
that recommendations include that governments should only award patents where
“genuine innovation has occurred,” not undermine TRIPS through threats, better protect
countries that use international agreements to promote access to health technologies, and
take punitive measures against countries that use political or commercial pressure to
undermine international agreements). The Panel also proposes to close the health
innovation gap through non-market-driven ﬁnancing mechanisms like public–private
partnerships, product development partnerships, grants, and prizes. Id. at 31–32.
128. Council for Trade-Related Aspects of Intellectual Property Rights, Waiver from
Certain Provisions of the TRIPS Agreement for the Prevention, Containment and
Treatment of COVID-19, WTO Doc. IP/C/W/669 (Oct. 2, 2020), https://docs.wto.org/
dol2fe/Pages/SS/directdoc.aspx?ﬁlename=q:/IP/C/W669.pdf&Open=True
[https://perma.cc/ZL5S-N742].
129. See Thiru Balasubramaniam, 23 February 2021: South Africa’s Interventions at the
WTO TRIPS Council, Knowledge Ecology Int’l (Mar. 1, 2021), https://www.keionline.org/
35453 [https://perma.cc/3N27-QTZ4].
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negotiations [at the WTO] to make that happen.”130 The pharmaceutical
industry and wealthy countries like the United Kingdom, those in the
European Union, and others oppose the proposal to waive intellectual
property rights.131 Signiﬁcantly, the South African intervention before the
TRIPS Council notes that the countries opposing the waiver proposal account for 60% of the globally administered COVID-19 vaccines.132 In their
view, intellectual property rights are not a barrier to access, as the current
system is required to incentivize new inventions. The opposing countries
maintain that equitable access can be achieved through voluntary licensing and technology transfer arrangements, among other means.133 Yet, this
Piece has already illustrated the severe constraints of voluntary transfer
arrangements,134 and as South Africa’s ﬁrst intervention before the TRIPS
Council aptly put it, “the problem with philanthropy is that it cannot buy
equality.”135 Given the diametrically opposed positions on the proposal,
reaching a consensus (which is the way most decisions are made) in the
TRIPS Council is unlikely in the immediate future.136
Accordingly, the goal of delivering “triple billion” COVID-19 vaccine
doses to the world’s most vulnerable populations appears elusive given the
current impasse.137 In January 2021, the Director-General of the WHO
warned that the world is on the “brink of a catastrophic moral failure––
130. Statement from Ambassador Katherine Tai on the COVID-19 Trips Waiver, Off. of
the U.S. Trade Representative (May 5, 2021), https://ustr.gov/about-us/policy-offices/
press-office/press-releases/2021/may/statement-ambassador-katherine-tai-covid-19-tripswaiver [https://perma.cc/4MWK-HJCJ].
131. UK Mission to the WTO, UN and Other International Organizations, UK
Statement to the TRIPS Council: Item 15 Waiver Proposal for COVID-19 (Oct. 16, 2020),
https://www.gov.uk/government/news/uk-statement-to-the-trips-council-item-15 (on ﬁle
with the Columbia Law Review).
132. Carien du Plessis, S.A. Accuses States Opposed to Vaccine Patent Waiver of Being
Pressurised by Big Pharma, Fin24 (Feb. 24, 2021), https://www.news24.com/ﬁn24/
economy/sa-accuses-states-opposed-to-vaccine-patent-waiver-of-being-of-being-pressurisedby-big-pharma-20210224 [https://perma.cc/Q5BJ-C88W].
133. See Ana Danaiya Usher, South Africa and India Push for COVID-19 Patents Ban,
396 Lancet 1790, 1790–791 (2020).
134. See supra notes 109–110 and accompanying text.
135. Aruna Kashyap & Margaret Wurth, Opinion, Rich Countries Must Stop ‘Vaccine
Apartheid’, Euronews, https://www.euronews.com/2021/03/11/rich-countries-must-stopvaccine-apartheid-view [https://perma.cc/4WG4-5VZJ] (last updated Mar. 11, 2021).
136. At the time of writing, states failed to reach agreement via consensus at the March
10–11, 2021 meeting on the intellectual property waiver request by South Africa and India.
It is supposed to be discussed prior to the next TRIPS Council meeting scheduled in June
2021. See Members Discuss TRIPS Waiver Request, Exchange Views on IP Role Amid a
Pandemic, WTO News (Feb. 23, 2021), https://www.wto.org/english/news_e/news21_e/
trip_23feb21_e.htm [https://perma.cc/Q9VD-9L3H]; see also Andrew Green, TRIPS
Waiver Tripped Up in WTO by ‘Third Way’, Devex (Mar. 5, 2021), https://www.devex.com/
news/trips-waiver-tripped-up-in-wto-by-third-way-99329 [https://perma.cc/PP2B-PMYA];
Jonathan Josephs, New WTO Boss Warns Against Vaccine Nationalism, BBC (Feb. 16, 2021),
https://www.bbc.com/news/business-56079088 [https://perma.cc/G98K-C26U].
137. Rich Countries Hoarding COVID Vaccines, supra note 83.
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and the price of this failure will be paid with lives and livelihoods in the
world’s poorest countries.”138 If the current course is not corrected,
vaccine apartheid will only deepen, and the resulting maldistribution will
render historically subordinated groups even more disposable. That
exacerbating racial subjugation was not the intention of law and
policymakers in the intellectual property regime when structuring legal
incentives for research and pharmaceutical innovation is immaterial.
Indeed, this does not render the impact of further entrenching racial
subordination any less acute. Nor does it alleviate the obligation of actors
to remedy the inequitable racialized disparities with vaccine access that
have resulted with COVID-19.
CONCLUSION
The twin pandemics of COVID-19 and systemic racism and the
responses to halt their spread have fundamentally challenged the status
quo. The uprising and its insistence on the value of Black lives creates an
opening to rethink, reshape, and create new possibilities for antisubordination efforts. Yet, as this Piece shows, the presumption of the disposability
of people of color implicitly persists in disparate areas of law and policy.
This Piece highlights several areas for reformation and restructuring. Further research should aim to reconcile the inconsistencies between the
rights to health and equality provided by international human rights law
on the one hand and trade-related intellectual property rights on the
other. Additionally, addressing systemic police violence, racialized global
health inequities, and medical experimentation and exploitation, as well
as vaccine apartheid and redlining, will require a signiﬁcant level of legal
reform and restructuring to counteract years of entrenched racial subordination. This Piece makes clear that changing the baseline of disposability
is required to begin to shift how people, society, and laws respond to Black
lives now and in the future.

138. Id.

